TELO vs. PRLD, GLSI, CAPR, IXHL, LFCR, IVA, OMER, SCPH, RIGL, and ACRV
Should you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Prelude Therapeutics (PRLD), Greenwich LifeSciences (GLSI), Capricor Therapeutics (CAPR), Incannex Healthcare (IXHL), Lifecore Biomedical (LFCR), Inventiva (IVA), Omeros (OMER), scPharmaceuticals (SCPH), Rigel Pharmaceuticals (RIGL), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical preparations" industry.
Prelude Therapeutics (NASDAQ:PRLD) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
Prelude Therapeutics received 25 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
Prelude Therapeutics presently has a consensus target price of $5.25, suggesting a potential upside of 31.25%. Given Telomir Pharmaceuticals' higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Telomir Pharmaceuticals.
79.7% of Prelude Therapeutics shares are held by institutional investors. 62.8% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Prelude Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.
In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.82 beat Telomir Pharmaceuticals' score of 0.59 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.
Summary
Telomir Pharmaceuticals beats Prelude Therapeutics on 5 of the 9 factors compared between the two stocks.
Get Telomir Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telomir Pharmaceuticals Competitors List
Related Companies and Tools
